Kristin Brooks, Associate Editor09.11.15
Charles River Labs recently acquired Celsis International for $212 million, expanding its Endotoxin and Microbial Detection (EMD) position with rapid endotoxin testing and bacterial identification systems for biopharmaceutical manufacturing.
Celsis provides rapid bacterial detection systems for quality control testing that are principally used for product-release testing to help ensure the safe manufacture of drugs and consumer products. The comprehensive EMD and Celsis portfolio is expected to drive increased adoption of EMD’s quality control testing solutions across both sterile and non-sterile applications.
Contract Pharma discusses the strategy behind the acquisition and the increasingly important area of quality control testing with Foster T. Jordan, corporate senior vice president, endotoxin and microbial detection, Charles River Laboratories. –KB
Contract Pharma: What was the strategy behind the Celsis acquisition?
Foster T. Jordan: Our strategi
FREE SUBSCRIPTION
Continue reading this story and get 24/7 access to Contract Pharma for FREE
FREE SUBSCRIPTION
